The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksB&M Regulatory News (BME)

Share Price Information for B&M (BME)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 521.20
Bid: 521.00
Ask: 521.20
Change: -6.60 (-1.25%)
Spread: 0.20 (0.038%)
Open: 529.80
High: 533.00
Low: 520.60
Prev. Close: 527.80
BME Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal

11 Mar 2020 07:00

RNS Number : 6960F
B&M European Value Retail S.A.
11 March 2020
 

 

 

 

11 March 2020

B&M European Value Retail S.A.

 

Sale of German Business

 

B&M European Value Retail S.A. (the "Company" or the "Group") announces that, following the strategic review in relation to the Group's German business, which was announced in November 2019, it has exchanged contracts today for the sale of J.A. Woll-Handels GmbH ("Jawoll").

 

The sale is for the Group's entire 80% shareholding (the "Shares") in Jawoll to a purchasing consortium led by AC Curtis Salta GmbH, a company funded by Adiuva Capital. The purchaser consortium also includes Wiebke Stern, Sebastian Dorin, Alexander Dorin, STIWEC GmbH and Jalogy Beteiligungs GmbH.

 

Completion of the transaction, which is conditional upon, among other things, German competition authority clearance being granted, is expected to occur within the next 28 days or by a long stop date of 1 June 2020.

 

Subject to completion, the total consideration payable to the Group for the transaction is €12,501,000 which is to be paid in cash. €2,501,000 is payable on completion of the transaction and €10,000,000 is payable on 31 December 2020 conditional on the on-going trading of Jawoll. In addition, on completion the purchaser's consortium will repay Jawoll's bank debt, which has a facility limit of up to €16m, and had been guaranteed by the Group.

 

The total consideration payable to the Group comprises:

(i) €2,500,000 as a part repayment of an intra-group trading account balance of €5,600,000 owed by Jawoll to the Group with the remaining balance having been waived;

(ii) €10,000,000 part repayment of loans made by the Group to Jawoll of €42,980,000 (including interest) with the balance of those loans having been waived; and

(iii) a nominal sum of €1,000 for the Shares.

Accordingly, the transaction will not have a material impact on the Group's leverage.

 

Jawoll, together with its wholly owned subsidiary, Jawoll Vertriebs GmbH ("Vertriebs"), is a general merchandise discount retailer with 89 stores in the North-West of Germany. The consolidated losses of those entities as reported for the financial year ended 31 March 2019 was £15.4m and the value of their Gross Assets as at 28 September 2019 (under IFRS16) was £192.6m.

 

The sale of Jawoll (together with its wholly owned subsidiary) constitutes a Class 2 transaction for the purposes of the UK Financial Conduct Authority's Listing Rules, and, as such does not require B&M shareholders' approval.

 

One of the purchaser's consortium, STIWEC GmbH ("STIWEC"), is an existing shareholder owning 13% of the shares of Jawoll. Another member of the purchaser's consortium, Jalogy Beteiligungs GmbH ("Jalogy"), is an investment company owned by Ralf Hartwich. Mr Hartwich is the Managing Director of Jawoll and Vertriebs and he is also an existing shareholder owning 7% of the shares of Jawoll. The transaction falls within the exemption in Listing Rule 11 Annex 1 Paragraph 9 of transactions to which the related party transaction rules do not apply, as it relates to shares in an insignificant subsidiary undertaking of B&M's Group.

 

The transaction does however constitute a related party transaction under the Luxembourg Law of 24 May 2011 (as amended on 1 August 2019). For the purpose of that law the Company confirms as follows. The related parties are STIWEC and Jalogy and the nature of their relationships with Jawoll and Vertriebs is as set out above in this Announcement. They have no other material relationships with the Company or any other entities in the B&M Group. The date of the transaction is the date of this Announcement. The value and net financial impact to the B&M Group of the transaction is as set out above in this Announcement. The sale transaction with the purchaser consortium includes the sale of 11% of the total issued shares in Jawoll to STIWEC and 8.45% of the total issued shares in Jawoll to Jalogy, for part of the nominal consideration (as referred to above in this Announcement) to be paid for the Shares. The transactions with those parties forms part of the terms of the overall sale transaction with the purchaser consortium, in respect of which the total consideration for the sale transaction is set out above. That consideration reflects the loss making position of Jawoll and its subsidiary as described above.

 

This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation.

 

 

Enquiries

 

B&M European Value Retail S.A.

For further information please contact +44 (0) 151 728 5400

Simon Arora, Chief Executive

Paul McDonald, Chief Financial Officer

Steve Webb, Investor Relations Director

Investor.relations@bandmretail.com

 

Media

For media please contact +44 (0) 207 379 5151

Maitland

Daniel Yea

bmstores-maitland@maitland.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DISJBMBTMTTBMLM
Date   Source Headline
18th Jan 202211:11 amRNSHolding(s) in Company
18th Jan 202211:01 amRNSDirector/PDMR Shareholding
14th Jan 20227:00 amRNSResult of Secondary Placing of Ordinary Shares
13th Jan 20224:45 pmRNSProposed Secondary Placing of Ordinary Shares
13th Jan 20221:05 pmRNSBlock listing Interim Review
6th Jan 20227:00 amRNSQ3 FY22 Trading Update
30th Dec 20214:58 pmRNSPost Stabilisation Notice
9th Dec 20217:00 amRNSSpecial Dividend
24th Nov 202111:02 amRNSDirector/PDMR Notice
17th Nov 20213:48 pmRNSPricing of Senior Secured Notes Offering
15th Nov 20218:16 amRNSLaunch of Senior Secured Notes Offering
11th Nov 20217:00 amRNSFY22 Interim Results
10th Nov 20214:19 pmRNSHolding(s) in Company
10th Nov 202111:42 amRNSResult of Ordinary General Meeting
30th Sep 20219:00 amRNSTotal Voting Rights
30th Sep 20219:00 amRNSOrdinary General Meeting
16th Sep 20219:26 amRNSDirector/PDMR Shareholding
8th Sep 20219:36 amRNSTrading Update
12th Aug 20217:00 amRNSBoard Appointment
4th Aug 20218:00 amRNSBlock Listing Application
3rd Aug 202111:12 amRNSDirector/PDMR Shareholding
2nd Aug 202110:32 amRNSTotal Voting Rights
29th Jul 202112:16 pmRNSResult of AGM
20th Jul 202112:35 pmRNSDirector Declaration
16th Jul 20218:00 amRNSDirector/PDMR Shareholding
14th Jul 202111:22 amRNSDirector/PDMR Shareholding
13th Jul 20219:00 amRNSBlock listing Interim Review
8th Jul 20217:00 amRNSTrading Statement
21st Jun 20217:00 amRNSAnnual Financial Report
3rd Jun 20217:00 amRNSBoard Change
3rd Jun 20217:00 amRNSPreliminary Results
15th Mar 202110:16 amRNSHolding(s) in Company
4th Mar 20217:00 amRNSTrading Update
1st Mar 20219:48 amRNSTotal Voting Rights
25th Feb 20219:20 amRNSDirector Declaration
22nd Feb 20215:06 pmRNSDirector/PDMR Securities
10th Feb 20212:16 pmRNSHolding(s) in Company
9th Feb 202110:05 amRNSHolding(s) in Company
27th Jan 20217:00 amRNSHolding(s) in Company
20th Jan 20213:17 pmRNSHolding(s) in Company
20th Jan 202111:02 amRNSHolding(s) in Company
15th Jan 20214:02 pmRNSHolding(s) in Company
14th Jan 202112:52 pmRNSDirector/PDMR Shareholding
13th Jan 20219:24 amRNSBlock listing Interim Review
12th Jan 202110:00 amRNSDirector Declaration
12th Jan 20217:00 amRNSResults of Placing
11th Jan 20215:22 pmRNSProposed Secondary Placing
7th Jan 20217:00 amRNSTrading Statement
29th Dec 20209:25 amRNSDirector/PDMR Securities
29th Dec 20209:18 amRNSDirector/PDMR Securities

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.